BioCentury | Jul 28, 2020
Product Development

TCR2 gains on first signs of cell therapy efficacy in solid tumors

...T cell therapies against the target are in Phase I testing. TCR2 is also developing TC-110...
BioCentury | Jan 4, 2019
Financial News

TCR2 seeks IPO as first program slated to enter clinic

...early this year. Initial data are expected 2H19. The company plans to submit INDs for TC-110...
BioCentury | Dec 28, 2018
Financial News

TCR2 seeks IPO as first program slated to enter clinic

...early next year. Initial data are expected 2H19. The company plans to submit INDs for TC-110...
...million in venture funding since its inception in 2015. Elizabeth S. Eaton TC-210 TCR2 Therapeutics Inc. CD19 Mesothelin Mucin 16 (MUC16) (CA125) TC-110 TC-220...
Items per page:
1 - 3 of 3